| Followers | 0 |
| Posts | 1357 |
| Boards Moderated | 0 |
| Alias Born | 03/20/2022 |
Thursday, August 18, 2022 6:03:34 PM
So the fda will need more data and evidence to accept a new endpoint that drastically lowers the bar from the original one?
That means theyll have to unblind the data up to patient 710.
Really now!?!
That means theyll have to unblind the data up to patient 710.
Really now!?!
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
